Nautilus Biotechnology, Inc. (NAUT) Form 8-K — Sep 11, 2026
Nautilus Biotechnology entered into a Sales Agreement with TD Securities (USA), LLC (TD Cowen) on September 11, 2026, establishing a new at-the-market equity program for aggregate sales proceeds of up to $125,000,000, with TD Cowen acting as sales agent for compensation of up to 3.0% of gross proceeds. Simultaneously, the Company and TD Cowen mutually terminated the prior ATM Sales Agreement dated February 28, 2024; notably, no shares of common stock were ever sold under that earlier program. Sales under the new program are entirely at the Company's discretion and are conditioned on its new Form S-3 shelf registration statement being declared effective.
Key figures
- Gross Proceeds
- 125000000
- Par value
- $0.0001 per share
- Prior atm
- February 28, 2024 Sales Agreement with TD Cowen mutually terminated; no common stock was ever sold under it
- Program type
- at-the-market (ATM) equity program
- Agent commission
- up to 3.0% of gross proceeds
- Counsel fee caps
- $100,000 at execution, $25,000 per bring-down date, $20,000 FINRA filing legal expenses
- Termination notice
- either party may terminate on ten days' notice, or immediately on a material adverse change
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.